Unlocking Envelope: A New Strategy for a Functional Cure Through Antibody-Dependent Cell-Mediated Cytotoxicity

Project Details

Description

Public Health Relevance Statement/Narrative Persistent reservoirs of cells latently infected by human immunodeficiency virus (HIV-1) can potentially be reactivated to produce virus, creating impediments to HIV-1 eradication or cure. CD4-mimetic compounds sensitize virus-expressing cells to antibody-dependent cellular cytotoxicity (ADCC). The objective of this proposal is to provide a proof of concept for the value of conjugates of a CD4-mimetic compound, M48U1, with potent ADCC-mediating antibodies recognizing highly-conserved epitopes on HIV-1 envelope glycoproteins for their ability in reducing the size of the viral reservoir which could expedite application to HIV-1-infected humans.
StatusFinished
Effective start/end date1/07/1730/06/22

Funding

  • National Institute of Allergy and Infectious Diseases: $498,498.00
  • National Institute of Allergy and Infectious Diseases: $448,961.00
  • National Institute of Allergy and Infectious Diseases: $456,569.00
  • National Institute of Allergy and Infectious Diseases: $2,333,272.00
  • National Institute of Allergy and Infectious Diseases: $484,873.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.